Free Trial

Stocks, Yields Dip as J&J Vaccine Efficacy Shy of Estimates, But Strength in the Details

EQUITIES

Equity futures and US yields initially dipped on Johnson & Johnson's release of their COVID-19 vaccine candidate efficacy, with the data showing 66% effectiveness in global trial results. It appears the South African variant is dragging the headline lower, with the vaccine 72% effective in the US, 66% in Latin America but just 57% in South Africa.

  • Nonetheless, some positive signals are in the details of the release, with the vaccine candidate proving 85% effective in preventing severe disease across all regions studied, demonstrating complete protection against COVID-related hospitalization and death, 28 days post-vaccination.

Full Johnson & Johnson press release here.

MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.